CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤的 CAR-NK 细胞治疗：下一步该做什么？
英文原题：CAR-NK cell therapy for glioblastoma: what to do next?
查看英文原题
CAR-NK cell therapy for glioblastoma: what to do next?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤是中枢神经系统发病率及死亡率最高的恶性肿瘤，常规手术切除联合放疗或化疗复发率高、预后差，患者5年生存率不足10%。在肿瘤免疫治疗中，以嵌合抗原受体修饰T细胞为代表的CAR-T 细胞疗法在血液肿瘤中取得了巨大成功，但CAR-T 细胞在胶质母细胞瘤等实体瘤中的应用仍面临诸多挑战。CAR-NK细胞是继CAR-T 细胞之后另一种潜在的过继细胞治疗策略。与CAR-T 细胞疗法相比，CAR-NK细胞具有相似的抗肿瘤作用，同时CAR-NK细胞还能规避CAR-T 细胞疗法的一些不足，是肿瘤免疫领域的研究热点。本文就CAR-NK细胞在胶质母细胞瘤中的临床前研究现状，以及CAR-NK在胶质母细胞瘤中面临的问题和挑战进行综述。
展开英文摘要原文
Glioblastoma is a malignant tumor with the highest morbidity and mortality in the central nervous system. Conventional surgical resection combined with radiotherapy or chemotherapy has a high recurrence rate and poor prognosis. The 5-year survival rate of patients is less than 10%. In tumor immunotherapy, CAR-T cell therapy represented by chimeric antigen receptor-modified T cells has achieved great success in hematological tumors.
However, the application of CAR-T cells in solid tumors such as glioblastoma still faces many challenges. CAR-NK cells are another potential adoptive cell therapy strategy after CAR-T cells. Compared with CAR-T cell therapy, CAR-NK cells have similar anti-tumor effects. CAR-NK cells can also avoid some deficiencies in CAR-T cell therapy, a research hotspot in tumor immunity. This article summarizes the preclinical research status of CAR-NK cells in glioblastoma and the problems and challenges faced by CAR-NK in glioblastoma.
论文信息
- 作者
- Xiong Q、Zhu J、Zhang Y、Deng H
- 单位
- Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in oncology2023
- 原文标识
- PubMed 37404752 · DOI 10.3389/fonc.2023.1192128
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →